Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

@article{Mercuro2020RiskOQ,
  title={Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).},
  author={Nicholas J Mercuro and C. F. Yen and David J Shim and T. Maher and Christopher M McCoy and P. Zimetbaum and H. Gold},
  journal={JAMA cardiology},
  year={2020}
}
Importance Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)-associated pneumonia carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias. Objective To characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of hydroxychloroquine with or without concomitant azithromycin. Design, Setting, and Participants This was a cohort study performed at… Expand
Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
...
1
2
3
4
5
...

References

SHOWING 1-9 OF 9 REFERENCES
Azithromycin and the risk of cardiovascular death.
Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients
COVID-19 and Cardiovascular Disease